MEP and Neuromuscular Blocker
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04768400|
Recruitment Status : Recruiting
First Posted : February 24, 2021
Last Update Posted : April 28, 2021
|Condition or disease||Intervention/treatment||Phase|
|Brain Tumor||Drug: Arm I (MEP)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Quantitative Analysis Between Neuromuscular Blocking Agent and Motor Evoked Potential and Analysis of Risk Factors for the Coefficient of Variance of Motor Evoked Potential in Patients Undergoing Brain Tumor Removal Surgery: Population Approach|
|Actual Study Start Date :||March 9, 2021|
|Estimated Primary Completion Date :||March 1, 2022|
|Estimated Study Completion Date :||March 31, 2022|
Neuromuscular blockade will be performed using rocuronium.
Drug: Arm I (MEP)
Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.
- Amplitude of the motor evoked potential [ Time Frame: At intraoperative 0 hr from the start of the anesthetic induction ]Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the start of the anesthetic induction.
- Amplitude of the motor evoked potential [ Time Frame: At intraoperative 0 h from the opening of the dura ]Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the opening of the dura.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04768400
|Contact: Dong woo Hanfirstname.lastname@example.org|
|Korea, Republic of|
|Seoul, Korea, Republic of|
|Contact: DongWoo DongWoo 82-2-2019-4601 email@example.com|
|Contact: DongWoo DongWoo 82-2-2019- ext 2740|